Experimental Medicine Trials in Multiple Sclerosis Research Funding Opportunity

Funding Agency:
Progressive MS Alliance

The International Progressive MS Alliance has released a Request for Applications (RFA) to support innovative Experimental Medicine Trials that advance our knowledge of disease pathophysiology by defining the underlying mechanisms of an intervention, mechanisms of progressive MS pathogenesis, and/or harmonizing outcome measures that correlate with clinical efficacy for any given intervention.

The RFA offers two funding pathways: an Experimental Medicine Trial Award for up to €1.5 million or a Development Award for up to €100,000 that will result in a subsequent opportunity to apply for a full Experimental Medicine Trial Award. Development Awards are for planning, developmental efforts, and/or validation opportunities that support future trials. The inclusion of people with MS in the development of Alliance initiatives is valuable and essential, and all proposed applications must be developed with, and informed by, perspectives of people affected by progressive MS, including trial design and execution.


  • Pre-Application: March 15, 2024
  • Full Applications: March 29, 2024

Agency Website

Eligibility Requirements

A single PI located at a public institution or non-profit research organization must be identified as the overall leader for the entire project and the award must be administered at the organization where the PI is employed. Unless otherwise discussed with the Alliance, the PI must be a scientist focused on basic, clinical, or epidemiological research who is considered eligible by his or her institution to apply for a research grant. Projects that include investigators from multiple institutions and organizations are strongly encouraged. 

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

March 15, 2024